References
- StewartMWCritical appraisal of ranibizumab in the treatment of diabetic macular edemaClin Ophthalmol201371257126723836955
- Ranibizumab for treating diabetic macular oedema (rapid review of technology appraisal guidance 237) [webpage on the Internet]LondonNational Institute for Health and Clinical Excellence2013 Available from: http://publications.nice.org.uk/ranibizumab-for-treating-diabeticmacular-oedema-rapid-review-of-technology-appraisal-guidance-ta274Accessed August 31, 2013
- GroverSMurthyRKBrarVSChalamKVComparison of retinal thickness in normal eyes using Stratus and Spectralis optical coherence tomographyInvest Ophthalmol Vis Sci20105152644264720007831
- Wolf-SchnurrbuschUECeklicLBrinkmannCKMacular thickness measurements in healthy eyes using six different optical coherence tomography instrumentsInvest Ophthalmol Vis Sci20095073432343719234346
- LeungCKCheungCYWeinrebRNComparison of macular thickness measurements between time domain and spectral domain optical coherence tomographyInvest Ophthalmol Vis Sci200849114893489718450592
- Bentaleb-MachkourZJouffroyERabilloudMGrangeJDKodjikianLComparison of central macular thickness measured by three OCT models and study of interoperator variabilityScientific World Journal2012201284279522973177
References
- NguyenQDBrownDMMarcusDMRISE RIDE Research GroupRanibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDEOphthalmology2012119478980122330964
- Ranibizumab for treating diabetic macular oedema (rapid review of technology appraisal guidance 237) [webpage on the Internet]LondonNational Institute for Health and Clinical Excellence2013 Available from: http://publications.nice.org.uk/ranibizumab-for-treating-diabeticmacular-oedema-rapid-review-of-technology-appraisal-guidance-ta274Accessed October 10, 2013
- GroverSMurthyRKBrarVSChalamKVComparison of retinal thickness in normal eyes using Stratus and Spectralis optical coherence tomographyInvest Ophthalmol Vis Sci20105152644264720007831
- Wolf-SchnurrbuschUECeklicLBrinkmannCKMacular thickness measurements in healthy eyes using six different optical coherence tomography instrumentsInvest Ophthalmol Vis Sci20095073432343719234346
- LeungCKCheungCYWeinrebRNComparison of macular thickness measurements between time domain and spectral domain optical coherence tomographyInvest Ophthalmol Vis Sci200849114893489718450592
- Diabetic Retinopathy Clinical Research NetworkScottIUEdwardsARA phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edemaOphthalmology20071141860186717698196
- Diabetic Retinopathy Clinical Research NetworkComparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab for DME (Protocol T) Available from: http://clinicaltrials.gov/show/NCT01627249. NLM identifier: NCT01627249Accessed October 15, 2013
- ElmanMJBresslerNMQinHDiabetic Retinopathy Clinical Research NetworkExpanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edemaOphthalmology201111860961421459214
- DoDVNguyenQDKhwajaAAREAD-2 Study GroupRanibizumab for edema of the macula in diabetes study: 3-year outcomes and the need for prolonged frequent treatmentJAMA Ophthalmol2013131213914523544200